Tiziana reports last of 48 patients dosed in Phase 2a INFORM-MS trial evaluating two doses of intranasal foralumab versus placebo in non-active secondary progressive multiple sclerosis across leading US centers. Topline data are expected in late Q3/early Q4 2026 with presentation planned at the October ACTRIMS-ECTRIMS meeting in Toronto.
Tiziana has completed dosing of the final patient in its Phase 2a INFORM-MS trial, enrolling 48 non-active secondary progressive MS patients across multiple US clinical sites including Brigham and Women’s, Johns Hopkins and Yale.
The randomized, double-blind, placebo-controlled trial compares two intranasal foralumab doses against placebo, measuring microglial activation via PET scans and clinical outcomes such as EDSS, quality of life and fatigue scales over a 12-week treatment period.
Topline safety, tolerability and efficacy data are expected in late Q3 or early Q4 2026, with results slated for presentation at the October ACTRIMS-ECTRIMS meeting in Toronto.
Intranasal foralumab, the only fully human anti-CD3 mAb in clinical development via nasal delivery, aims to modulate immune responses directly in the nasal mucosa with potential CNS effects, offering a novel approach for neuroinflammatory diseases.
